WO2020197059A3 - Procédé permettant d'induire une différenciation de cellules souches en cellules cartilagineuses, à l'aide d'acide folique, d'un dérivé d'acide folique ou d'un inhibiteur d'acide folique - Google Patents

Procédé permettant d'induire une différenciation de cellules souches en cellules cartilagineuses, à l'aide d'acide folique, d'un dérivé d'acide folique ou d'un inhibiteur d'acide folique Download PDF

Info

Publication number
WO2020197059A3
WO2020197059A3 PCT/KR2020/000190 KR2020000190W WO2020197059A3 WO 2020197059 A3 WO2020197059 A3 WO 2020197059A3 KR 2020000190 W KR2020000190 W KR 2020000190W WO 2020197059 A3 WO2020197059 A3 WO 2020197059A3
Authority
WO
WIPO (PCT)
Prior art keywords
folic acid
inducing differentiation
cells
stem cells
cartilage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2020/000190
Other languages
English (en)
Korean (ko)
Other versions
WO2020197059A2 (fr
Inventor
정병문
문윤아
엄소연
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ewha Womans University
Original Assignee
Ewha Womans University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ewha Womans University filed Critical Ewha Womans University
Publication of WO2020197059A2 publication Critical patent/WO2020197059A2/fr
Publication of WO2020197059A3 publication Critical patent/WO2020197059A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0655—Chondrocytes; Cartilage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne : une composition permettant d'induire une différenciation de cellules souches en cellules cartilagineuses, comprenant de l'acide folique, un dérivé d'acide folique ou un inhibiteur d'acide folique ; un procédé permettant d'induire une différenciation de cellules souches en cellules cartilagineuses ; et une composition pharmaceutique destinée au traitement de maladies endommageant le cartilage, contenant des cellules cartilagineuses différenciées par le procédé permettant d'induire une différenciation.
PCT/KR2020/000190 2019-03-28 2020-01-06 Procédé permettant d'induire une différenciation de cellules souches en cellules cartilagineuses, à l'aide d'acide folique, d'un dérivé d'acide folique ou d'un inhibiteur d'acide folique Ceased WO2020197059A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2019-0035580 2019-03-28
KR1020190035580A KR102197871B1 (ko) 2019-03-28 2019-03-28 엽산, 엽산 유도체, 또는 엽산 저해제를 이용한 줄기세포의 연골세포로의 분화 유도 방법

Publications (2)

Publication Number Publication Date
WO2020197059A2 WO2020197059A2 (fr) 2020-10-01
WO2020197059A3 true WO2020197059A3 (fr) 2021-04-29

Family

ID=72611616

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2020/000190 Ceased WO2020197059A2 (fr) 2019-03-28 2020-01-06 Procédé permettant d'induire une différenciation de cellules souches en cellules cartilagineuses, à l'aide d'acide folique, d'un dérivé d'acide folique ou d'un inhibiteur d'acide folique

Country Status (2)

Country Link
KR (1) KR102197871B1 (fr)
WO (1) WO2020197059A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102377420B1 (ko) * 2021-04-26 2022-03-21 에스케이케미칼 주식회사 피리메타민을 유효성분으로 포함하는 류마티스 관절염의 치료 또는 예방용 약학 조성물
KR102307115B1 (ko) 2021-05-12 2021-10-01 주식회사 스마트셀랩 시프로플록사신에 의한 줄기세포의 연골전구세포로의 유도 및 연골세포로의 분화
KR102780154B1 (ko) * 2021-09-17 2025-03-11 이화여자대학교 산학협력단 항엽산제를 포함하는 중간엽줄기세포의 연골분화용 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100990436B1 (ko) * 2009-11-30 2010-10-29 동국대학교 산학협력단 중간엽 줄기세포를 ＤＫＫ-1 또는 ｓＦＲＰ-1을 이용하여 연골세포로 분화시키는 방법
KR20170108325A (ko) * 2016-03-17 2017-09-27 차의과학대학교 산학협력단 성체줄기세포의 연골세포 분화용 조성물 및 분화 방법
JP2017535405A (ja) * 2014-12-01 2017-11-30 アドヴァンスト・キトサン・ソリューションズ・バイオテック キトサン及び軟骨細胞を含む軟骨修復のための軟骨ゲル

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITTO20060282A1 (it) 2006-04-14 2007-10-15 Univ Degli Studi Torino Mezzo di coltura e composizione farmaceutica per la rigenerazione del tessuto cartilagineo relativo procedimento relativi usi e prodotti
US8414928B2 (en) 2006-12-06 2013-04-09 George R. Dodge Methods for the generation of cartilage-like material by mechanical loading
GB201111244D0 (en) 2011-06-30 2011-08-17 Konink Nl Akademie Van Wetenschappen Knaw Culture media for stem cells
KR101419836B1 (ko) * 2012-05-10 2014-07-16 서울대학교산학협력단 Δ5-2-옥소피페라진 유도체를 포함하는 중간엽 줄기세포의 연골세포로의 분화 유도용 조성물
JP6725806B2 (ja) 2015-06-18 2020-07-22 高雄醫學大學Ｋａｏｈｓｉｕｎｇ Ｍｅｄｉｃａｌ Ｕｎｉｖｅｒｓｉｔｙ 軟骨細胞の生成促進薬物を製造するための医薬組成物の用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100990436B1 (ko) * 2009-11-30 2010-10-29 동국대학교 산학협력단 중간엽 줄기세포를 ＤＫＫ-1 또는 ｓＦＲＰ-1을 이용하여 연골세포로 분화시키는 방법
JP2017535405A (ja) * 2014-12-01 2017-11-30 アドヴァンスト・キトサン・ソリューションズ・バイオテック キトサン及び軟骨細胞を含む軟骨修復のための軟骨ゲル
KR20170108325A (ko) * 2016-03-17 2017-09-27 차의과학대학교 산학협력단 성체줄기세포의 연골세포 분화용 조성물 및 분화 방법

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KAPPEN CLAUDIA, MELLO MARIA ALICE, FINNELL RICHARD H., SALBAUM J. MICHAEL: "Folate modulatesHox gene-controlled skeletal phenotypes", GENESIS, WILEY-LISS, vol. 39, no. 3, 1 July 2004 (2004-07-01), pages 155 - 166, XP055803985, ISSN: 1526-954X, DOI: 10.1002/gene.20036 *
SAHAKYAN VARDINE, DUELEN ROBIN, TAM WAI LONG, ROBERTS SCOTT J., GROSEMANS HANNE, BERCKMANS PIETER, CECCARELLI GABRIELE, PELIZZO GL: "Folic Acid Exposure Rescues Spina Bifida Aperta Phenotypes in Human Induced Pluripotent Stem Cell Model", SCIENTIFIC REPORTS, vol. 8, no. 1, 1 December 2018 (2018-12-01), pages 1 - 19, XP055803980, DOI: 10.1038/s41598-018-21103-8 *

Also Published As

Publication number Publication date
WO2020197059A2 (fr) 2020-10-01
KR20200114226A (ko) 2020-10-07
KR102197871B1 (ko) 2021-01-04

Similar Documents

Publication Publication Date Title
EP4306529A3 (fr) Inhibiteurs de fgfr et leurs procédés d'utilisation
MX2021006283A (es) Derivados heteroaromáticos para uso como regulador, método de preparación de los mismos y uso de los mismos.
MX2023012981A (es) Compuestos para inhibir o degradar proteinas objetivo, composiciones que los comprenden, metodos para su preparacion y metodos para usarlos.
MX2022015531A (es) Derivado de piridina-pirimidina, metodo de preparacion y uso farmaceutico del mismo.
GEP20227434B (en) 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer
PH12020550881A1 (en) Substituted bicyclic heterocyclic compounds as prmt5 inhibitors
EP4365179A3 (fr) Nouveaux dérivés de rapamycine
SG10201902206QA (en) Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
AU2012204982A8 (en) 2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as FAK/Pyk2 inhibitors
NO20076093L (no) Substituerte amidderivater som proteinkinaseinhibitorer
IN2014KN00929A (fr)
NO20090723L (no) Kondenserte heterosykliske derivater og fremgangsmater for anvendelse
UA99882C2 (uk) Похідні бензофуранілу, фармацевтична композиція та спосіб лікування захворювань (варіанти)
BR112014015720A2 (pt) derivados de tieno[3,2-d]pirimidina que têm atividade inibidora de proteinas quinases
PH12023552079A1 (en) Cdk2 inhibitors and methods of using the same
AU2012249851A8 (en) MicroRNA compounds and methods for modulating miR-21 activity
MX2023001296A (es) Composiciones y metodos para tratar enfermedades y trastornos.
PH12019500394A1 (en) Bicyclic nitrogenated heterocyclic compound
PH12022550843A1 (en) Thienopyrimidones as trpa1 inhibitors
MX2016009759A (es) Inhibidores de neprilisina.
MX2023005591A (es) Metodos de tratamiento de enfermedades y trastornos.
ZA202107777B (en) Voruciclib polymorphs and methods of making and using thereof
WO2024026479A3 (fr) Inhibiteurs de cdk2 et leurs procédés d'utilisation
WO2024026486A3 (fr) Inhibiteurs de cdk2 et leurs procédés d'utilisation
WO2024026483A3 (fr) Inhibiteurs de cdk2 et leurs procédés d'utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20777763

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20777763

Country of ref document: EP

Kind code of ref document: A2